A semaglutide microdose usually means a clinician-prescribed amount below the standard labeled starting dose of 0.25 mg once weekly, but there is no official medical definition. Cost depends on the provider, pharmacy, and formulation. At Chia, compounded semaglutide injection plans currently start at $249/month, with microdosing plans available after clinician review.
Wondering if semaglutide is right for you? Take the 3-min clinical quiz.
See if you qualify →What is the quick answer on microdose semaglutide?
Semaglutide microdosing generally means using a lower clinician-prescribed amount than the labeled starting dose of 0.25 mg once weekly for Wegovy. It is not an FDA-approved dosing schedule, and there is no single definition that applies across pharmacies or clinics 7.
The main patient questions are usually practical: “How much does it cost?” and “How many units is that?” The cost answer depends on the program. The units answer depends on the concentration of your vial, so it cannot be guessed safely from a social media chart or another person’s prescription.
- A microdose is usually below the labeled 0.25 mg weekly starting dose, but no FDA label defines a semaglutide microdose.
- Chia offers compounded semaglutide injection, with plans currently starting at $249/month.
- A syringe unit is a volume marking, not a dose in milligrams.
- Standard semaglutide trials studied specific labeled or trial doses, not most microdose schedules.
- Nausea, vomiting, diarrhea, constipation, and abdominal pain are common semaglutide side effects listed in FDA labels 7 8.
What counts as a microdose of semaglutide?
Semaglutide microdosing is usually used to describe a clinician-guided dose below the labeled Wegovy starting dose of 0.25 mg once weekly. Because no FDA label defines “microdose,” the exact amount can vary by provider, formulation, and patient goal 7.
That distinction matters. Wegovy (semaglutide, a GLP-1 receptor agonist) is FDA-approved for chronic weight management in specific patients, while Ozempic (semaglutide) and Rybelsus (oral semaglutide) have diabetes-focused labeled uses; compounded semaglutide via a 503A pharmacy is a separate compounded prescription pathway and is not FDA-approved 7 8 9 10.
Why there is no official FDA-approved microdose schedule
FDA labels describe the studied product, route, dose escalation, warnings, and adverse reactions for approved products. The Wegovy label starts at 0.25 mg once weekly for the first 4 weeks and then escalates in steps toward maintenance dosing; it does not include a lower microdose schedule 7.
Clinicians may consider lower-dose approaches for tolerability or personalization, but that is different from saying the approach has the same evidence base as labeled dosing. Side effects still matter at low doses, especially gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, and abdominal pain 7.
How much does microdose semaglutide cost?
Microdose semaglutide pricing varies by provider, pharmacy, visit model, and whether medication is included. At Chia, compounded semaglutide injection plans currently start at $249/month, and microdosing plans are available only after licensed provider review.
If you are comparing options, look at the full monthly cost, not just the advertised medication price. Include the clinical visit, follow-up support, pharmacy source, supplies, shipping, and whether the program explains milligrams, units, and concentration clearly. For a broader pricing overview, see our guide to semaglutide cost.
How Chia prices compounded semaglutide injection from $249/month
Chia’s semaglutide offering is a compounded semaglutide injection, prescribed only when clinically appropriate after an online health questionnaire and licensed US provider review. Medications are compounded by state-licensed US 503A pharmacies and shipped to the patient’s door.
| Option | What it means | Chia availability | Starting price listed by Chia |
|---|---|---|---|
| Compounded semaglutide injection | Injectable semaglutide prescribed after clinical review and filled through a licensed 503A pharmacy | Available through Chia | From $249/month |
| Microdosing plan | Provider-guided lower-dose approach when clinically appropriate | Available for Chia semaglutide injection | Included in semaglutide plan pricing when prescribed |
| Oral semaglutide pill | Oral semaglutide is described in the Rybelsus label for type 2 diabetes, but oral compounded semaglutide is not listed in Chia’s catalog | Not offered by Chia for semaglutide | Not listed |
| Weight + Energy protocol | NAD+ Injection plus choice of GLP-1 | Available through Chia | From $309/month |
3-min quiz
Explore clinician-reviewed semaglutide access
Chia offers compounded semaglutide injection with microdosing plans available when clinically appropriate. A licensed US provider reviews your health history before any prescription, and a prescription is not guaranteed. Compounded drugs are not FDA-approved.
How do semaglutide milligrams compare with syringe units?
Milligrams measure the amount of semaglutide. Units on a syringe measure volume, and a unit-to-milligram conversion cannot be known without the drug concentration on the pharmacy label.
This is one of the most common safety issues with compounded injectable medications. A “10 unit” mark on a U-100 insulin syringe can represent different milligram amounts depending on whether the vial concentration is, for example, lower or higher. The FDA has warned about risks with unapproved GLP-1 products, including dosing errors and quality concerns 10.
When to ask your prescriber or pharmacist before injecting
Ask before injecting if the label, syringe, or instructions do not clearly match. You should know the prescribed dose in milligrams, the vial concentration, the syringe type, and the exact volume your prescriber or pharmacist told you to measure.
| Term | What it means | Why it matters |
|---|---|---|
| Milligram, or mg | The amount of active drug | This is the medical dose your prescriber uses |
| Milliliter, or mL | The volume of liquid | This changes based on concentration |
| Unit on U-100 syringe | A syringe volume marking; 100 units equals 1 mL on a U-100 syringe | Units do not equal mg by themselves |
| Drug concentration | How many mg are in each mL | You need this to convert volume to dose |
| Pharmacy label | The source of truth for your dispensed vial | Do not use another person’s chart or vial directions |
Can you lose weight on 0.25 mg, 0.2 mg, or another low semaglutide dose?
Semaglutide has strong human trial evidence for weight loss at studied doses, including 2.4 mg once weekly in major STEP trials. But evidence for 0.2 mg, other microdoses, or long-term microdose-only plans is more limited, and individual results vary 6.
In STEP 1, adults with overweight or obesity without diabetes received once-weekly semaglutide 2.4 mg with lifestyle intervention and lost more weight on average than those receiving placebo; the same section of the evidence also reports gastrointestinal side effects, which were common with semaglutide 6. In STEP 4, continuing semaglutide after an initial run-in helped maintain and extend weight loss compared with switching to placebo, again with safety monitoring built into the trial 2.
Lower doses may be used by clinicians to improve tolerability or to individualize treatment, but we should be honest about the evidence gap. If the question is “Is 0.2 mg enough for me?” the safe answer is that it depends on your medical history, goals, side effects, and response, and it should be decided with a licensed clinician.
Why microdosing evidence is more limited than standard-dose evidence
Most large semaglutide weight-loss trials were designed around labeled or trial dose schedules, not flexible microdose-only plans. STEP 8 compared weekly semaglutide with daily liraglutide in adults with overweight or obesity without diabetes, while STEP 6 studied semaglutide in an East Asian population with overweight or obesity; these trials help explain semaglutide’s effect as studied, not the exact results of compounded microdosing 1 4.
Compounded formulations do not have FDA-evaluated outcomes data. That does not mean a licensed clinician cannot prescribe a compounded medication when appropriate, but it does mean results from branded-product trials should not be treated as guaranteed outcomes for a compounded prescription 10.
How does microdose semaglutide compare with standard semaglutide dosing?
Microdose semaglutide may be considered when a clinician wants a lower, slower approach, while standard dosing follows a labeled schedule. The tradeoff is that standard dosing has stronger trial evidence, while microdosing may require more individualized monitoring and has less direct research.
Semaglutide works by activating GLP-1 receptors, which can affect appetite regulation, satiety, gastric emptying, and blood glucose control 7 8. Those same mechanisms can also cause side effects, especially nausea, vomiting, diarrhea, constipation, abdominal pain, and possible risks that labels warn clinicians to review before treatment 7 8.
| Question | Microdose approach | Standard labeled or trial approach |
|---|---|---|
| Evidence strength | Less direct evidence for specific low-dose schedules | Stronger randomized-trial and label-based evidence for studied doses |
| Tolerability | May be chosen to try a slower start, but side effects can still occur | Dose escalation is designed to help tolerability, but GI side effects remain common |
| Speed of results | May be slower or less predictable | More data exist for average results at studied doses |
| Monitoring | Needs clear clinician and pharmacy instructions, especially with units | Still needs monitoring for side effects, contraindications, and response |
| Regulatory status | Microdosing is not an FDA-approved semaglutide schedule | FDA labels define approved product schedules and warnings |
Stopping semaglutide can also matter. In the STEP 1 extension, participants regained weight after withdrawal of semaglutide and some cardiometabolic improvements moved back toward baseline, which supports thinking about weight care as ongoing treatment rather than a short reset 5.
Microdose semaglutide at Chia: injection, clinician review, and home delivery
Chia offers compounded semaglutide injection with microdosing plans available after licensed provider review, and plans currently start at $249/month. The process is online, but it is still medical care: a prescription is never guaranteed.
Here is how it works at Chia. You complete a short online health questionnaire. A licensed US provider reviews your history, medications, goals, and safety factors. If semaglutide is clinically appropriate, the medication is compounded by a state-licensed US 503A pharmacy and shipped to your door.
Dosing is provider-guided and adjusted over time. Patients can message the care team through the patient portal between visits, which is especially important if nausea, vomiting, diarrhea, constipation, abdominal pain, low appetite, or injection questions come up 7. If you are still comparing access paths, our guide to finding a microdose GLP-1 near you explains what to check before starting.
| Chia step | What happens | Why it matters |
|---|---|---|
| Online questionnaire | You share health history, medications, and goals | Helps the provider assess eligibility and risks |
| Licensed provider review | A US clinician reviews whether treatment is appropriate | Semaglutide requires medical evaluation |
| Provider-guided dosing | Dose decisions and changes are guided over time | Helps reduce guesswork and dosing errors |
| 503A pharmacy fulfillment | Medication is compounded by a state-licensed US 503A pharmacy | Avoids no-prescription or research-use sources |
| Home delivery and portal support | Medication ships to your door; you can message the care team | Supports follow-up and safety questions |
Chia also offers related protocols for people whose provider feels they fit: Weight + Energy, which includes NAD+ Injection plus choice of GLP-1, and Weight + Muscle, which includes Sermorelin Injection plus choice of GLP-1. These are separate clinical decisions, not automatic add-ons.
Who may not be eligible for semaglutide?
Semaglutide is not right for everyone, even at a low dose. FDA labels include important warnings and contraindications, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and they describe risks that clinicians review before prescribing 7 8.
Pregnancy and breastfeeding require special caution. Semaglutide labels include pregnancy-related risk information, and a clinician should review pregnancy plans, breastfeeding, contraception, and timing before treatment 7 8.
People using insulin or insulin secretagogues for type 2 diabetes may need closer monitoring because glucose-lowering medicines can increase hypoglycemia risk when combined 8. A history of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney issues related to dehydration, or prior serious reactions also needs careful review because semaglutide labels include warnings in these areas 7 8.
- Tell your clinician if you are pregnant, breastfeeding, or planning pregnancy.
- Share all diabetes medicines, especially insulin or sulfonylureas.
- Mention any history of pancreatitis, gallbladder disease, severe vomiting, or dehydration-related kidney problems.
- Report a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
- Seek urgent care for severe abdominal pain, persistent vomiting, signs of dehydration, or symptoms of a serious allergic reaction.
What should you ask before starting microdose semaglutide?
Microdose semaglutide should come with clear answers before the first injection, especially about the exact milligram dose, vial concentration, syringe type, and follow-up plan. If a seller does not require a prescription, that is not a legitimate medical pathway.
The FDA has raised concerns about unapproved GLP-1 products used for weight loss, including risks from unapproved sources and dosing errors 10. Patients should not use research chemicals, gray-market semaglutide, or products labeled “not for human use.”
- 1What is my prescribed dose in milligrams, and what volume should I measure?
- 2What is the exact concentration printed on my pharmacy label?
- 3Which syringe am I supposed to use?
- 4What side effects should I report right away?
- 5How will my provider monitor weight, nutrition, blood glucose risk, and tolerability?
- 6What happens if I miss a dose, have vomiting, or cannot eat enough protein?
- 7Is this medication coming from a state-licensed pharmacy with a valid prescription?
Medication is only one part of weight care. Protein intake, resistance training, sleep, and follow-up matter for preserving lean mass during weight loss; our protein calculator for weight loss can help you discuss nutrition targets with your care team.
3-min quiz
Start a semaglutide eligibility review
If you want a clinician-reviewed path, Chia offers compounded semaglutide injection with online evaluation, provider-guided dosing, 503A pharmacy fulfillment, and home delivery when prescribed. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
Frequently asked questions
Start with Chia’s online eligibility quiz. A licensed US provider reviews your health history and decides whether semaglutide is clinically appropriate. A prescription is not guaranteed.
There is no official FDA definition. In practice, it usually means a clinician-prescribed amount below the labeled 0.25 mg once-weekly Wegovy starting dose.
Chia’s compounded semaglutide injection plans currently start at $249/month. Microdosing plans are available when a licensed provider decides they are clinically appropriate.
It depends. Standard-dose semaglutide has stronger trial evidence than microdose schedules, and results are not established for compounded formulations. Compounded drugs are not FDA-approved.
You cannot know from the unit number alone. Units measure syringe volume, not milligrams. The conversion depends on the medication concentration printed on your pharmacy label.
No. Ozempic, Wegovy, Rybelsus, and compounded semaglutide are different prescription pathways with different labels, forms, and instructions. Do not switch products or doses without clinician guidance.
Nausea, vomiting, diarrhea, constipation, abdominal pain, reflux, low appetite, and dehydration can occur. Serious risks are less common but need medical review, especially pancreas, gallbladder, kidney, allergy, and thyroid-related concerns.
No. Semaglutide should be used only with a valid prescription and a licensed pharmacy. Do not use research chemicals, gray-market products, or anything labeled not for human use.
References
- 1.Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
- 2.Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
- 3.Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology. 2017.
- 4.Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022.
- 5.Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity & Metabolism. 2022.
- 6.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. 2021.
- 7.U.S. Food and Drug Administration. Wegovy prescribing information. 2024.
- 8.U.S. Food and Drug Administration. Ozempic prescribing information. 2024.
- 9.U.S. Food and Drug Administration. Rybelsus prescribing information. 2024.
- 10.U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if semaglutide is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
